Current plans regarding Liothyronine

Becky Warwick made this Freedom of Information request to Department of Health and Social Care

This request has been closed to new correspondence from the public body. Contact us if you think it ought be re-opened.

The request was successful.

Dear Department of Health,
Please can you tell me what you plan to do about Liothyronine being withdrawn and how you plan to improve thyroid treatment in the future?

Yours faithfully,
Becky Warwick

Department of Health,

 

Our ref: DE-1108646

 

Dear Ms Warwick,
 
Thank you for your correspondence of 24 November about liothyronine.  I
have been asked to reply.

 

I appreciate your concerns.

 

The Freedom of Information Act only applies to recorded information such
as paper or electronic archive material.  As your correspondence asked for
general information, rather than requesting recorded information or
documentation, it did not fall under the provisions of the Act.

 

NHS England’s consultation on the draft guidance on low-value prescription
items was developed in partnership with NHS Clinical Commissioners on
behalf of clinical commissioning groups (CCGs), and was based on the
latest clinical evidence, including that from the National Institute for
Health and Care Excellence.  The guidance seeks to ensure that the NHS is
able to secure best value from its use of medicines and so focuses on
areas of prescribing that have been found to be unsafe or ineffective, or
where there are more cost-effective alternatives. 

 

In the consultation, NHS England proposed that liothyronine should not be
prescribed routinely.  As you know, this proposal caused significant
concern among patients who are currently prescribed liothyronine.  NHS
England has, however, decided that it should continue to be prescribed,
but only in secondary care.

 

The final commissioning guidance is addressed to CCGs to support them in
fulfilling their duties to use prescribing resources appropriately.  It
will need to be taken into account by CCGs in their own guidance to
clinicians in primary care.  In issuing the final guidance, careful
consideration has been given to the responses to the consultation, to
ensure that particular groups of people are not disproportionately
affected, and that principles of best practice on clinical prescribing are
adhered to.

 

With regard to improving thyroid treatment, you may wish to direct your
enquiries to NHS England, which has overall responsibility for the NHS in
England.  The contact details are:

 

NHS England

PO Box 16738

Redditch B97 9PT

 

Tel: 0300 311 22 33

Email: [1][email address]

I hope this reply is helpful.

Yours sincerely,
 
Ola Adigun
Ministerial Correspondence and Public Enquiries
Department of Health

 

-------------------------------------------------------------------------------------------------------------------------

Please do not reply to this email. To contact the Department of Health,
please visit the [2]Contact DH section on Gov.uk

To receive news about DH: [3]sign up to our monthly newsletter

 

 

show quoted sections

Incoming and outgoing e-mail messages are routinely monitored for
compliance with the Department of Health's policy on the use of electronic
communications. For more information on the Department of Health's e-mail
policy click here http://www.dh.gov.uk/terms

--------------------------------------------------------------------------

This email was scanned by the Symantec virus scanning service and was
certified virus free.
Communications may be automatically logged, monitored and/or recorded for
legal purposes.

References

Visible links
1. mailto:[email address]
2. https://www.gov.uk/government/organisati...
3. http://r1.surveysandforms.com/4c3zqo08-a...

Looking for an EU Authority?

You can request documents directly from EU Institutions at our sister site AskTheEU.org . Find out more .

AskTheEU.org